Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab
Open Access
Abstract
A 49-year-old male Japanese patient was admitted to our hospital under the diagnosis of COVID-19 pneumonia. For 5 days before admission, he had experienced various symptoms, including high fever, watery diarrhea, dyspnea, and cough, and he tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid. The patient is a smoker who was on medication for hypertension. A chest computed tomography scan showed bilateral multiple patchy ground-glass opacities. Despite being treated with several therapeutic agents, he still exhibited dyspnea (oxygen saturation [SpO2] in ambient air: 88%), a high fever (axillary temperature: 39 °C), and high blood pressure (148/98 mmHg). Because laboratory data revealed high levels of C-reactive protein (CRP; 2.10 mg/dL) and urinary β2-microglobulin (B2M; 33,683 µg/mL), the anti-interleukin-6 receptor antibody tocilizumab (TCZ; 400 mg) was administered intravenously. One day after injection, he was afebrile. Four days after the TCZ injection, his CRP level dropped to 0.27 mg/dL, B2M level decreased to 3817 µg/mL, and viral load became low. No adverse drug reaction due to TCZ was observed. The patient was discharged 15 days after admission. The early administration of TCZ in this patient prevented the pneumonia and kidney injury caused by COVID-19 from progressing to hyperinflammation syndrome.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP17H01690)
This publication has 34 references indexed in Scilit:
- Molecular pharmacology of ciclesonide against SARS-CoV-2Journal of Allergy and Clinical Immunology, 2020
- Cytokine storm intervention in the early stages of COVID-19 pneumoniaCytokine & Growth Factor Reviews, 2020
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19Antimicrobial Agents and Chemotherapy, 2020
- Favipiravir, an antiviral for COVID-19?Journal of Antimicrobial Chemotherapy, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, ChinaClinical Infectious Diseases, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamilyStem Cells, 1994